Alison F Floyd

US Patent:

6911455, Jun 28, 2005

Filed:

Dec 13, 2000

Appl. No.:

10/149722

Inventors:

Alison G. Floyd - Durham NC, US
Mir A Hashim - Durham NC, US
Peiyuan Lin - Durham NC, US
Robert A. Mook - Durham NC, US
Andrea Sefler - Durham NC, US
Kathleen Cornell Meserve - Durham NC, US
Patricia Neal Ricciarelli - Durham NC, US
Timothy David Spitzer - Durham NC, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K031/47
A61K031/165

US Classification:

514308, 424 44

Abstract:

The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipients for use in the formulations of the invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.

US Patent:

20050287177, Dec 29, 2005

Filed:

Nov 7, 2003

Appl. No.:

10/533325

Inventors:

Gary Goodson - Durham NC, US
Alison Floyd - Durham NC, US
Cecilia Navy - Durham NC, US

Assignee:

Glaxo Group Unlimited and Smithkline Beecham Corp. - Research Triangle Park NC

International Classification:

A61K009/00

US Classification:

424400000

Abstract:

A pharmaceutical composition comprising 3′-azido-3′-deoxythymidine and (2R,cis)-4-amino--(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one suitable for once daily administration

US Patent:

20070184109, Aug 9, 2007

Filed:

Jun 2, 2004

Appl. No.:

10/557912

Inventors:

Alison Floyd - Durham NC, US
Cecilia Navy - Durham NC, US
Gary Goodson - Durham NC, US

International Classification:

A61K 31/403
A61K 31/445

US Classification:

424465000, 424464000, 514319000, 514415000

Abstract:

A pharmaceutical composition comprising 5HTreceptor agonist or a pharmaceutically acceptable derivative thereof in combination with an NSAID or pharmaceutically acceptable derivative thereof wherein the 5HTreceptor agonist and NSAID are located in discrete zones with respect to each other wherein each zone comprises the active ingredient and optionally a carrier. A preferred composition comprises sumatriptan succinate and naproxen sodium.

US Patent:

59425105, Aug 24, 1999

Filed:

Dec 9, 1997

Appl. No.:

8/973798

Inventors:

Alison Green Floyd - Raleigh NC
Sunil Jain - Cary NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 3153

US Classification:

514242

Abstract:

A lyophilized formulation of lamotrigine having been prepared by lyophilizing a frozen sterile aqueous solution of Imotrigine mesylate in which the pH is from 2. 4 to 4.

US Patent:

20140309287, Oct 16, 2014

Filed:

Dec 6, 2013

Appl. No.:

14/099586

Inventors:

CHRISTOPHER P. RUSCONI - Durham NC, US
DOUGLAS BROOKS - Durham NC, US
ALISON G. FLOYD - Raleigh NC, US

Assignee:

REGADO BIOSCIENCES, INC. - Basking Ridge NJ

International Classification:

A61K 47/20
A61K 31/7088
A61K 47/48

US Classification:

514 44 R

Abstract:

The present invention relates generally to pharmaceutical formulations of conjugated oligonucleotides, such as pegylated aptamers, as well as to a method of preparing and using the same. The pharmaceutical formulations have desirable shelf life characteristics under varied storage conditions. Formulations of oligonucleotides or oligonucleotides conjugates and methods for their preparation and use are provided having a shelf life of at least about 24 months or, more preferably, at least about 36 months at about 2 to about 30 C. In particular embodiments, the formulations have a pH of about 7 or less and contain methionine. Optionally, dissolved oxygen content is reduced during the manufacturing process is used to improve desired shelf life characteristics.